Menu
NASP

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and latest CE information More Information

Featured Activity

This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

IBD Module #1: Inflammatory Bowel Disease and the Role of Specialty Pharmacy Services

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE) 

 
 View more NASP/CSPE Activities
 

Activity Description

Inflammatory Bowel Disease (IBD) describes a group of chronic conditions such as ulcerative colitis, Crohn's Disease and indeterminate colitis, all of which can have a severe impact on a patient's quality of life. IBD can cause additional complications and systemic manifestations, resulting in hospitalization. There are numerous factors to consider in selecting optimal drug therapies for IBD. Coordination and continuity of patient care is essential in IBD. This activity addresses treatment goals, options for therapy, monitoring parameters and the pharmacist's role in IBD therapy management.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

  • Outline signs and symptoms of IBD
  • Identify factors to consider in treatment selection for IBD
  • Describe the clinical pharmacist’s role in IBD therapy management
  • Describe the specialty pharmacy service role in IBD therapy management

Faculty

Nehrin Khamo
Clinical Pharmacist/Team Leader
Specialty Pharmacy Services University Of Illinois
Hospital & Health Sciences System

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Nehrin Khamo has no relevant commercial or financial relationships to disclose.

The opinions expressed in this activity should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

CE Accreditation

Release Date: 03-10-2017
Expiration Date: 03-10-2019

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-17-094-H01-P has been assigned to this knowledge-based home-study CE activity. This activity is approved for 0.75 contact hour (0.075 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

This activity is partially funded by an educational grant from UCB, Inc.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.